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ABSTRACT  
 2 
Design of inhibitors for N-myristoyltransferase (NMT), an enzyme responsible for protein 
trafficking in P. falciparum, the most lethal species of parasites that cause malaria, is 
described. Chemistry-driven optimization of hit compound 1 from a focused NMT inhibitor 
library led to the identification of two early lead compounds 4 and 25, which showed good 
enzyme and cellular potency and excellent selectivity over human NMT. These molecules 
provide a valuable starting point for further development. 
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INTRODUCTION 
 
Malaria, a disease caused by protozoan parasites of the genus Plasmodium, is a demanding 
health problem. The most lethal form, caused by P. falciparum, was responsible for nearly 
655,000 deaths in 2010, mainly of children below the age of five.1 Although recent vaccine 
trials are giving promising results,2 chemotherapy remains the mainstay of anti-malarial 
treatment. Since chloroquine has lost its efficacy in most endemic areas due to the rapid 
development of drug resistance,3 artemisinin-based combination therapies serve as the current 
gold standard.4 Recently, signs of emerging resistance to artemisinins5 have led to renewed 
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efforts to develop novel anti-malarial agents, with purely synthetic tri/tetraoxane and 
spiroindolone among the most promising candidates.6-10  
The enzyme N-myristoyltransferase (NMT) represents a promising drug target,11 since it 
has been shown to be essential in many organisms.12-15 NMT, a monomeric enzyme 
ubiquitous in eukaryotes, catalyzes an irreversible co-translational or post-translational 
transfer of myristate (C14:0 fatty acid) from myristoyl-coenzyme A (myr-CoA) to the N-
terminal glycine of a subset of eukaryotic proteins.16, 17 Although genetic knockdown of 
NMT in P. falciparum has yet to be achieved presumably due to its essentiality, 
myristoylated proteins such as glideosme-associated protein-45, ADP-ribosylation factor-1 
and calcium-dependent protein kinase-1 have been characterized and shown to be critical for 
parasite viability.18-21 Furthermore, a novel inducible knockout of NMT in the closely related 
mammalian pathogen P. berghei has demonstrated an acute dependence on NMT activity in 
the parasite life cycle.22 It seems likely that inhibition of myristoylation also has an equal 
potential to disrupt key biological pathways in P. falciparum.  
N-myristoylation by NMT follows an ordered Bi-Bi mechanism, in which the binding of 
myr-CoA to NMT occurs prior to the protein substrate.23 Binding of myr-CoA facilitates the 
opening of a second pocket, to which the protein substrate binds. Transfer of myristate to the 
protein substrate takes place via a nucleophilic addition-elimination reaction and this is 
followed by ordered release of CoA and the myristoylated protein. In contrast to the myr-
CoA pocket which is highly conserved across species, the peptide binding cavity is more 
divergent. As a result, inhibitors of fungal NMTs have been discovered by several research 
groups that are competitive with the protein substrate and show excellent selectivity relative 
to human NMT.24-29 
A “piggy-back” approach30 was used to identify compound 129 (Figure 1) as a hit by 
screening a focused library of reported C. albicans NMT (CaNMT)24-29 and T. brucei NMT 
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(TbNMT) inhibitors.31,32 Compound 1, initially developed by Roche in an antifungal 
campaign,29 showed moderate inhibition against PfNMT and promising selectivity over 
human NMT1 (HsNMT1). 
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Figure 1. Structure and biological activity of compound 1 
Herein we report the design of potent and selective P. falciparum NMT (PfNMT) 
inhibitors based on the structure of compound 1. Crystal structures of NMT inhibitors 
enabled experimentally derived structure-activity relationships (SAR) to be interpreted and 
mutagenesis studies provided a rational basis for human enzyme selectivity. 
 
RESULTS AND DISCUSSION 
 
Investigation of the C-4 side chain. In the absence of structural information for 
Plasmodium NMT at that time, a chemistry-driven approach was adopted. Based on the 
structure of compound 1, C-4 and C-2 side chains were identified as promising sites for 
modification (Figure 2). Exploration of 24 variations in the C-4 side chain revealed SAR, 
which are similar to those Roche found in their CaNMT project:24 (i) trimethylene is an 
optimal chain length; (ii) a secondary amine X is preferred (Tables S1-S3, Supporting 
Information). Conformational restriction of the trimethylene side chain by replacement with 
4-piperidinol, resulted in the discovery of compound 2 (Figure 2). Compound 2 showed 3-
fold activity improvement over 1 while maintaining good human selectivity. In addition, 2 is 
more drug-like than 1 in terms of lower molecular weight, fewer rotatable bonds and is also 
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more synthetically tractable. Therefore, 4-piperidinol was considered to be an optimal C-4 
side chain. More importantly, this compound also displayed moderate anti-parasitic activity 
with an EC50 value of 15 µM.  
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Figure 2. Modification of C-4 side chain of compound 1 
 
    Investigation of the C-2 side chain. The study of the C-2 side chain began by varying the 
R2 group of the ester and replacement of the latter by an amide (Scheme 1). An N-Boc 
piperidinol side chain was incorporated into the readily synthesized benzofuran scaffold33 via 
a Mitsunobu reaction, followed by hydrolysis of the ethyl ester to provide 4-({1-[(tert-
butoxy)carbonyl]piperidin-4-yl}oxy)-3-methyl-1-benzofuran-2-carboxylic acid (I-2). The 
ester and amide with different R2 groups were synthesized under standard coupling 
conditions. Larger R2 groups, especially those including an aromatic ring (compounds 4, 5 in 
ester series and compounds 12, 13 in amide series), give rise to better enzyme inhibition in 
both series. Compound 4 represents a significant improvement in potency and has a sub-µM 
IC50 value of 0.27 µM. Introduction of a methylene moiety between R2 and the ester group 
was a key factor in this enhanced potency as phenyl ester (compound 3) is only moderately 
active, suggesting the importance of flexibility in the linker group Y. Furthermore, spacers 
longer than methylene (compounds 7, 8) significantly reduced the affinity, indicating that this 
spacing is optimal. Surprisingly, a huge loss of activity was found when the Y linker was 
altered from methylene ester 4 to a methylene amide 12; however, the deleterious effect of 
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the ester to amide swap is largely mitigated when the R2 phenyl in compound 5 is replaced by 
a napthyl in compound 13, prompting further investigation of the linker group Y to 
understand its role in binding. 
Scheme 1a. 
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a   Reagents: (a) DIAD, PPh3, N-Boc-4-OH piperidine, THF, r.t., 4 hr, 95%; (b) 5% TFA in 
DCM, r.t., 2 hr, quantitative; (c) LiOH, MeOH/H2O, 50 °C, 4 hr, 90%; (d) EDCI, HOBt, 
DIPEA, R2OH, CH3CN, r.t., 4 hr, 70-90%; (e) PyBOP, DIPEA, R2NH2, DMF/DCM, r.t., 3 hr, 
50-70%. 
 
Table 1. Activities of esters and amides against PfNMTa 
O
O
Y
NH
R2
 
No. Y R2 IC50 (µM)  No. Y R2 IC50 (µM) 
2 COO Et 16.5  8 COO(CH2)3 Ph 36.2 
3 COO Ph 24.4  9 CONH i-Pr >200 
4 COOCH2 Ph 0.27  10 CONH cyclo-hex >100 
5 COOCH2 α-napthyl 1.4  11 CONH Ph 28.8 
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6 COOCH2 cyclo-hex 9.7  12 CONHCH2 Ph 13.0 
7 COO(CH2)2 Ph 4.1  13 CONHCH2 α-napthyl 2.3 
a The IC50(PfNMT) values were averaged from two independent dose-response curves, the 
standard deviation was within 30% of the resulting values.  
 
 Investigation of linker group Y. Compounds containing rigid Y linkers with similar 
length (compounds 14-17) were initially synthesized (Scheme 2). These inhibitors 
(compounds 3, 11, 14-17, Table 2) were found to be only moderately active compared to their 
methylene ester analogues, such as 4, reinforcing the earlier conclusion that the flexibility of 
the Y linker group is crucial. Compounds with various types of flexible Y linkers 
(compounds 18-25, Table 2) were then prepared (Scheme 3). It is clear that a flexible linker 
alone, such as ethylene derivative 18, does not confer inhibitory activity. Introduction of a 
heteroatom in the ethylene linker (compounds 19, 20) improved enzyme affinity. Compounds 
22-25 were designed to mimic the original methylene ester, with a view to finding a more 
suitable replacement (Table 2). Both the carbonyl and the ester oxygen atoms in the 
methylene ester were found to contribute to potency since replacement of either atom by 
methylene (compounds 21, 22) led to a 40-fold activity drop. Removing a rotatable bond of 
the ethylene (compound 23) gave a 3-fold improvement in affinity, which appears to 
contradict the earlier interpretation that flexibility in the Y linker is important. It is possible 
that this particular rigid linker directs the pendant phenyl group into a specific hydrophobic 
cavity. The dramatic loss of activity in sulfone derivative 24 is unexpected and cannot be 
explained by the shorter length of the linker Y compared to the methylene ester because 
ketone derivative 14, which has an even shorter linker, retains some inhibitory activity with 
an IC50 of 22 µM. Therefore, it is likely that the methylene sulfone is incompatible with the 
binding site of the enzyme. 1,2,4-oxadiazole derivative 25, an ester bioisostere, exhibited 
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promising potency and selectivity although it was still less active than its ester counterpart. 
Given that none of the other Y linkers synthesized showed comparable inhibition, the 
methylene ester was selected as an optimal linker group (Figure 3). Next, a standard set of 
substituents (methyl, chloro and methoxy) were employed to find suitable substituents on the 
pendant phenyl ring in the methylene ester series. However, of the seven synthesized 
compounds, only the meta-methoxy substituent in compound 26 gave comparable potency to 
the parent compound 4 (Table S4, Supporting Information), indicating a tight R2 group 
binding pocket in the enzyme.  
These compounds in Table 2 were also applied to synchronized P. falciparum trophozoites 
(3D7 line). Consistent with the premise that NMT is a good target in Plasmodium, it was 
found that these inhibitors also showed promising anti-plasmodial effects in vitro, with the 
most potent PfNMT inhibitor 4 giving the highest anti-parasitic activity. These results imply 
that optimized PfNMT inhibitors have excellent potential to be developed into anti-malarial 
therapeutics. 
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a Reagents : (a) PhCOCH2Br, K2CO3, CH3CN, 80°C, 24 hr, 40%; (b) DIAD, PPh3, N-Boc-4-
OH piperidine, THF, r.t., 4 hr, 90%; (c) 5% TFA in DCM, r.t., quantitative; (d) LiAlH4, THF, 
0 °C to r.t., 2 hr, 90%; (e) MnO2, DCM, r.t., 24 hr, 77%; (f) benzyltriphenyl phosphonium 
bromide, NaOH, THF/H2O, r.t, 1 hr, 70% (including cis- and trans- isomers); (g) Pd/C, 1,4-
cyclohexadiene, EtOH, 80 °C, 4 hr, 40%; (f) i. R2(NH2)C=N-OH, EDCI, HOBt, DIPEA, 
CH3CN, r.t., 4 hr; ii. 4Å molecular sieve, dry toluene, 110 °C, 12 hr, 70% over two steps. 
Scheme 3a 
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a Reagents : (a) DIAD, PPh3, N-Tr-4-OH piperidine, THF, r.t., 4 hr, 65%; (b) LiAlH4, THF, 0 
°C to r.t., 2 hr, 90%; (c) DIAD, PPh3, phenol, THF, r.t., 4 hr, 5%; (d) 0.1% TFA, 0.2% H2O 
in DCM, r.t., 90%; (e) NaH, BnBr, DMF, r.t., 15%; (f) CH3COCH2Cl, K2CO3, CH3CN, 80°C, 
24 hr, 20%; (g) DIAD, PPh3, N-Boc-4-OH piperidine, THF, r.t., 4 hr, 90%; (h) benzaldehyde, 
NaOH, EtOH/H2O, 3 hr, 45%; (i) 5% TFA in DCM, r.t., quantitative; (j) Pd/C, 1,4-
cyclohexadiene, EtOH, 80 °C, 4 hr, 40%; (k) ethyl carbazate, EtOH/H2O, 80°C, 24 hr, 24%; 
(l) SOCl2, DMF, -20°C to r.t., 3 hr, 54%; (m) BnCl, K2CO3, dry acetone, 60°C, 6 hr, 24%; (n) 
m-CPBA, DCM, r.t., 1 hr, 50%. 
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Table 2. Activities of inhibitors containing different Y linkers against PfNMT and P. 
falciparuma  
O
O
Y
NH
R2
 
No. Y R2 IC50 (µM) S. I.b EC50 (µM) 
3 COO Ph 24.4 >20 10.0 
4 COOCH2 Ph 0.27 >400 1.2 
11 CONH Ph 28.8 >10 5.3 
13 CONHCH2 α-napthyl 2.3 28 2.4 
14 CO Ph 22.0 >5 5.3 
15 cis-CH=CH Ph 72.0 - - 
16 trans-CH=CH Ph 26.1 >10 n.d.c 
17 
N
N
O  
Ph 17.9 >12 n.d. 
18 CH2CH2 Ph 131 - - 
19 CH2O Ph 6.6 >16 n.d. 
20d SCH2 Ph 38.2 - - 
21 CH2OCH2 Ph 7.1 14 4.5 
22 CO(CH2)2 Ph 10.2 >20 4.0 
23 
O  
Ph 3.5 14 2.5 
24d SO2CH2 Ph >200 - - 
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25 
N
N
O  
Ph 2.0 >50 2.1 
26 COOCH2 3-OMe-Ph 0.60 >200 n.d. 
a The IC50(PfNMT) and EC50(P. falciparum, 3D7 line) values were averaged from two 
independent dose-response curves, the standard deviation was within 30% of the resulting 
values; b S.I. = Selectivity Index, calculated as IC50(HsNMT1) / IC50(PfNMT); c n.d. = not 
determined; d there is no methyl group at the C-3 position of the benzofuran scaffold.  
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Figure 3. Investigation of C-2 side chain  
 
Structure Studies. Although attempts to crystallize PfNMT have been unsuccessful, we 
have been able to determine co-crystal structures of P. vivax NMT (PvNMT) with a non-
hydrolysable myr-CoA analogue (NHM)34 and a series of benzofuran inhibitors. PvNMT 
shares 81% sequence identity with PfNMT, with only 2 out of 23 residues situated within 5Å 
of the ligand differing between the two enzymes (Y212 and Y334 in PvNMT are each 
replaced by Phe in PfNMT, Figure S1, Supporting Information). Selected compounds from 
Table 2 were assayed against PvNMT and similar levels of potency (<3-fold difference) to 
PfNMT were observed. Therefore, we consider that structures of PvNMT complexes can be 
used to rationalize the experimental SAR for the PfNMT inhibitors.  
Inhibitor 26 occupies what is expected to be the peptide binding pocket of PvNMT (Figure 
S2, Supporting information). Its key interactions with the enzyme are illustrated in Figure 4. 
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The secondary amino group of the piperidine establishes an ion-pair interaction with the C-
terminal carboxylate (L410) and a cation-dipole interaction with the phenolic hydroxyl of 
Y107. The ion-pair mimics the interaction of the α-amino groups of substrate peptides with 
the buried α-carboxylate of NMT (as observed in structures of S. cerevisiae NMT, 
ScNMT);35 moreover, similar interactions are formed by inhibitors of CaNMT29 and 
TbNMT.31 The carbonyl oxygen together with the oxygen atom of the benzofuran ring in 26 
participate in water-mediated hydrogen bonds with the hydroxyl of Y334, which may account 
for the superiority of the methylene ester over its less polar alkyl or ether/thioether 
equivalents (compounds 18-21). The methylene spacer in 26 allows the pendant aromatic 
group to be directed into a tight pocket, in agreement with the experimental SAR, where the 
phenyl group makes π-π interactions with F105 and forms further apolar interactions with 
residues V96, E97, D98, F103 and R104 that contribute to a loop that closes over the peptide 
binding pocket. Shorter (compound 3)or longer (compounds 7, 8) spacers than the methylene 
ester result in 10- to 100-fold lower inhibition, presumably because they prevent or 
compromise the binding of the attached phenyl group to this pocket. Meanwhile the meta-
methoxy oxygen in 26 forms a hydrogen bond with the hydroxyl of S319.  
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Figure 4. Crystal structure of 26 (1.50 Å resolution, PDB code: 4B14) co-crystallized with P. 
vivax NMT. Distances are given in Å. Atoms are colored: C yellow (enzyme) and green 
(inhibitor 26), N blue, O red, H2O red sphere. 
Inhibitors 22, 25 and 26 occupy almost identical binding positions in the enzyme (Figure 
5a). Interestingly, binding of these ligands rigidify the side chain of H213, which shows two 
distinct conformations in the unligated structure, but adopts a single conformation that forms 
water-mediated hydrogen bonds with Y linkers in these compounds (Figure 5a). This 
indicates an important role for H213 in binding, which is also documented in the binding of a 
peptide substrate in ScNMT.36 As seen from the experimental SAR, an amide Y linker is 
disfavored. The reason for this seemingly surprising result is clarified by examination of the 
bound structures of these two compounds. It is found that the carbonyl group in 13 adopts the 
opposite orientation to that of its ester equivalent in 26 (Figure 5b). We believe that this 
reflects different conformations in the free ligands, presumably due to a steric clash between 
methyl in the benzofuran scaffold and the hydrogen atom in the amide (Figure 6). 
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Furthermore, the side chain of H213 is observed to move away from the ligand upon the 
binding of 13 (Figure 5b). This amide carbonyl is hence too far away from either Y334 or 
H213 to form an interaction and the altered conformation of the spacer might affect the 
binding geometry of the pendant phenyl ring, which accounts for the large activity difference 
between amide 12 and ester 4. However, this difference is largely mitigated when the phenyl 
R2 group is replaced by a napthyl group (13 vs. 4), which makes more extensive π-π 
interactions with F105.  
 
Figure 5. Structural overlays of benzofuran NMT inhibitors: (a) 22 (1.84 Å resolution, PDB 
code: 4B12, C purple), 25 (1.58 Å resolution, PDB code: 4B13, C cyan) and 26 (PDB code: 
4B14, C green) share identical binding positions and rigidify the movement of H213 (binary 
complex, 1.56 Å resolution, PDB code: 4B10, C grey) to a single conformation (ternary 
complexes, C yellow); (b) opposite orientation adopted by the carbonyl moiety in 13 (1.59 Å 
resolution, PDB code: 4B11, C magenta) compared to the one in 26 (PDB code: 4B14, C 
green) push H213 away from the ligand. Atoms are colored: N blue, O red, H2O red sphere. 
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Figure 6. Geometry comparison of ester versus amide inhibitors: (a) Representation of the 
binding mode of the ester-containing inhibitor 26; (b) Representation of the binding mode of 
the amide-containing inhibitor 13; (c) Alternative conformation of inhibitor 13 does not adopt 
the conformation found in (a), due to a steric clash between the amide NH and the methyl 
group. 
 
Selectivity Studies. High inhibitor selectivity between Plasmodial and human NMTs is 
desirable because NMT is also expressed in human cells. Indeed, our benzofuran inhibitors 
displayed good to excellent selectivity over HsNMT1 (Table 2). This is surprising in the light 
of a recent high throughput screening campaign which suggests that strongly selective 
PfNMT inhibitors would not be easy to identify.37 The structures were therefore examined 
with a view to rationalizing the selectivity of the benzofuran compounds. 
We compared the structures of PvNMT in its binary complex with NHM and in the ternary 
complex with NHM and 26. The side chain of Y211 adopts an alternate conformation upon 
binding 26 so that there are stacking interactions with the benzofuran ring (Figure 7a). 
Following superimposition of the structures of PvNMT-NHM-26 and HsNMT1-Myr-CoA, it 
is apparent that the equivalent tyrosine (Y296) in the human enzyme occupies a position that 
would clash with 26 (Figure 7b). Given the weak inhibition of HsNMT1 by 26, we speculated 
that a higher energy barrier associated with the conformational change of Y296 in HsNMT1 
might be restricting binding. In contrast to 26, MRT57965, a PvNMT inhibitor showing little 
human selectivity,38 is accommodated in the Plasmodial enzyme with only minor changes in 
the conformation of Y211 (Figure 7c). It is predicted that similarly small conformational 
changes of Y296 would be required to accommodate this inhibitor in HsNMT1 (Figure 7d). 
We therefore hypothesized that steric hindrance by Y296 in HsNMT1 contributes to human 
selectivity for these benzofuran inhibitors.  
 16 
 
Figure 7. Investigation of selectivity over HsNMT1: (a) conformational change of Y211 in 
PvNMT-NHM (PDB code: 4B10) upon the binding of 26 (PDB code: 4B14); (b) HsNMT1-
Myr-CoA (PDB code: 3IU1) overlaid with PvNMT-NHM-26 complex (PDB code: 4B14). 
This indicates a clash between Y296 in HsNMT1 and 26; (c) conformational change of Y211 
in PvNMT-NHM (PDB code: 4B10) upon binding MRT57965 (PDB code: 4A95); (d) 
overlay of HsNMT1-Myr-CoA (PDB code: 3IU1) with PvNMT-NHM-MRT57965 (PDB 
code: 4A95). This suggests minimal conformational changes of that particular tyrosine when 
binding this inhibitor. Atoms are colored: C yellow (enzymes in the ternary complex), C grey 
(enzymes in the binary complex), C green (inhibitors), N blue, O red, S gold. 
To test this hypothesis, site-directed mutagenesis was used to substitute this tyrosine by 
alanine in both PvNMT and HsNMT1. The inhibitory activities of 25, 26 and MRT57965 
against the wild type and mutated NMTs were measured (Table 3) and used to calculate the 
ratio of the IC50 values for HsNMT1 and PvNMT (the selectivity index, SI) for the pair of 
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wild type enzymes and for the pair of alanine-substituted mutants. The alanine mutations are 
found to have significantly less selectivity for 26 and 25 than the wild-type enzymes, with 
decreases in the SI of 20-fold and >12-fold respectively. In contrast, the change in the SI for 
MRT57965 was only two-fold. Mutation of the human NMT leads to a four- to five-fold 
increase in affinity for compounds 25 and 26. This is consistent with the suggestion that 
changing tyrosine to the smaller alanine in HsNMT1 removes the potential clash and lowers 
the energy barrier required to accommodate these two inhibitors. On the other hand, under the 
conditions that only small conformational change is required to accommodate ligand binding 
(25, 26 and MRT5796 in PvNMT and MRT57965 in HsNMT1), such mutation exclusively 
led to weaker enzyme affinity, implying that this tyrosine facilitates inhibitor binding to 
NMTs unless the residue clashes with the bound ligand. The data experimentally demonstrate 
the contribution of this tyrosine (Y211 in PvNMT and Y296 in HsNMT1) to the human 
selectivity.    
 
Table 3. The inhibitory activity for mutants of PvNMT and HsNMT1a 
Inhibitor 
IC50 (µM) S.I.b 
Pv (WTc) 
Pv 
(Y211A) 
Hs1 (WT) 
Hs1 
(Y296A) 
WT MUd 
26 0.6 2.7 45 10 75 3.7 
25 6.2 16.6 >500 110 >80 6.6 
MRT57965e 32.7 150 115 218 3.5 1.5 
a The IC50 values were averaged from two independent dose-response curves; the standard 
deviation was within 30% of the resulting values; b S.I.=Selectivity Index, calculated by 
IC50(HsNMT1) / IC50(PvNMT); c WT = wild type; d MU = mutants; e Wild-type enzyme 
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result for MRT57965 was different from that reported by Goncalves38 due to different assay 
conditions, including the concentrations of enzyme, myr-CoA and different peptide substrate.  
CONCLUSION AND OUTLOOK 
     Chemistry-driven optimization of a screening hit allowed us to identify PfNMT inhibitor 4 
as an early lead candidate with good enzyme and cellular potency and excellent selectivity 
over human NMT. With the aid of structural information, the superiority of a benzyl ester 
side chain was rationalized and the interactions involved with the linker were mapped. 
Furthermore, the structural basis for inhibitory selectivity between HsNMT1 and PfNMT was 
found to be due to a clash between the inhibitor and residue Y296 in HsNMT1.  
Potential biological instability of the ester moiety may limit the scope of inhibitor 4. 
Oxadiazole 25, an ester bioisostere, showed some advantages given its biological stability 
and comparable cellular potency and human selectivity to 4; synthesis of oxadiazole 
analogues shall be the focus of further studies. As suggested by Figure 4, two hotspot 
residues (F105 and S319 in PvNMT, which are also conserved in PfNMT), are identified to 
involve a π-π interaction and hydrogen bond with aromatic R2 respectively. However, as the 
unsubstituted phenyl ring is still the best R2 among PfNMT inhibitors so far, it is unlikely that 
the hydrogen bond with S319 has been formed in PfNMT. Forming this missing hydrogen 
bond without affecting human selectivity, possibly by using N-containing heterocycles, has 
potential to further improve the enzyme potency. Finally, understanding the influence of 
physiochemical properties (such as pKa and cLogP) on the cellular potency is also important.  
 
EXPERIMENTAL SECTION 
 
CHEMISTRY 
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      General Methods. All solvents and reagents were purchased from commercial sources 
and used without further purification. The compounds were spotted on silica TLC plates 
(Merck, Si60, F254), visualized under UV-light at 254 nm or iodine over silica. Purification of 
the compounds for biological tests was performed on a Gilson semi-preparative reverse phase 
HPLC system (Anachem Ltd., Luton, UK) equipped with a HICHROM C18 Column (250 × 
21.2 mm), #306 pumps and a Gilson 155 UV/Vis detector. UV detection was at 220 nm. The 
mobile phase consisted of water plus 0.1% TFA (solvent A) and methanol plus 0.1% TFA 
(solvent B) with a gradient of 30% B for 2 min changing to 98% B over 30 min, maintaining 
for 2 min , and then down to 2% B over 0.5 min at a flow rate of 12 mL/min. The purities of 
the reported compounds for biological assay tests were evaluated by analytical LC-MS which 
was carried out on a Waters 2767 system equipped with a photodiode array and a mass 
spectrometer using an X-BridgeTM C18 column (5 µM, 4.6 x 100 mM). The mobile phase 
consisted of water plus 0.1% formic acid (solvent A) and methanol plus 0.1 formic acid 
(solvent B) with a gradient starting from 2% to 98% B over the first 10 min, maintaining for 
2 min, and down to 2% B over 1 min followed by the maintenance period for another 4 min 
at 2% B at a flow rate of 1.2 mL/min. One-dimensional 1H- and 13C-NMR spectra as well as 
two dimensional NMR spectra were recorded on Bruker AV at 400, 500 MHz or 100, 125 
MHz respectively. Chemical shifts are reported in ppm. Mass spectra were obtained from the 
Mass Spectrometry Service of Department of Chemistry, Imperial College London. Purity 
(>95%) and molecular mass of compounds for biological tests were confirmed by LC-MS 
and high resolution of mass spectrometry.  
 
      General Procedure of Mitsunobu Reaction.  t-Butyl 4-{[2-(ethoxycarbonyl)-3-methyl-
1-benzofuran-4-yl]oxy} piperidine-1-carboxylate (I-1) To a stirred solution of ethyl 4-
hydroxy-3-methylbenzofuran-2-carboxylate33 (2 g, 9.1 mmol), t-Butyl 4-hydrxypiperidine-1-
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carboxylate (4.56 g, 22.7 mmol) and triphenylphosphine (5.95 g, 22.7 mmol) in anhydrous 
THF (20 mL) was added DIAD (4.34 mL, 22.7 mmol) dropwise at room temperature. The 
resulting mixture was stirred at the same temperature for 4 hours, and then concentrated in 
vacuo. The residue was purified by column chromatography over silica gel, eluting with 
hexane: ethyl acetate, 5:1 to afford the title compound as colourless oil (3.52 g, 96% yield). 
1H-NMR (CDCl3, 400 MHz): δ 7.32 (t, J=8.0 Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 6.65 (d, J=8.0 
Hz, 1H), 4.74-4.69 (m, 1H), 4.46 (q, J=7.2 Hz, 2H), 3.68-3.61 (m, 2H), 3.58-3.52 (m, 2H), 
2.78 (s, 3H), 2.04-1.97 (m, 2H), 1.96-1.86 (m, 2H), 1.50 (s, 9H), 1.46 (t, J=7.2 Hz, 3H).  
 
      General Procedure for N-Boc Deprotection. Ethyl 3-methyl-4-(piperidin-4-yloxy) 
benzofuran-2-carboxylate (2) A mixture of compound I-1 (10 mg, 0.025 mmol) and TFA (50 
µL) in DCM (1 mL) was stirred at room temperature for 2 hours. The reaction mixture was 
evaporated under pressure to dryness, which was further purified by semi-preparative reverse 
phase HPLC to give the title compound as a white solid (9.8 mg, 94% yield). 1H-NMR 
(CD3OD, 400 MHz): δ 7.41 (t, J=8.4 Hz, 1H), 7.15 (d, J=8.4 Hz, 1H), 6.88 (d, J=8.0 Hz, 1H), 
4.98-4.93 (m, 1H), 4.42 (q, J=7.2 Hz, 2H), 3.50-3.40 (m, 2H), 3.33-3.28 (m, 2H), 2.80 (s, 
3H), 2.34-2.24 (m, 2H), 2.22-2.12 (m, 2H), 1.43 (t, J=7.2 Hz, 3H). 13C-NMR (CD3OD, 100 
MHz): δ 161.87, 157.38, 154.55, 141.09, 130.09, 127.02, 120.30, 106.50, 106.16, 69.95, 
62.13, 42.01, 28.28, 14.63, 11.82. Calculated exact mass for the protonated molecule 
(C17H22NO4): 304.1549; measured accurate mass (ESI): 304.1561. LC-MS purity: 100%, Rt = 
11.39 min.  
 
      Prototypical Procedure for Ester Analogues 3-8 and 26. Phenyl 3-methyl-4-(piperidin-
4-yloxy)-1-benzofuran-2-carboxylate(3) A mixture of compound I-2 (44 mg, 0.12 mmol), 
EDCI (25 mg, 0.13 mmol), hydroxybenzotriazole (22 mg, 0.15 mmol) in anhydrous 
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acetonitrile (3 mL) was stirred at room temperature for 30 minutes, and then treated with 
phenol (12.1 mg, 0.13 mmol) and DIPEA (41 µL, 0.24 mmol). The resulting mixture was 
further stirred at room temperature for another 12 hours. After that, the solution was 
evaporated to dryness in vacuo. The residue was re-dissolved in ethyl acetate (20 mL) and 
washed with 0.5 M NaOH and brine sequentially. The organic layer was dried over 
anhydrous sodium sulphate and concentrated in vacuo, to produce the N-Boc precursor 
without further purification. 
     The Boc-deprotection in DCM (2 mL) containing 5% TFA was carried out according to 
the preparation of compound 2, to afford the title compound as a white solid (28.1 mg, 51% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.50-7.43 (m, 3H), 7.32 (t, J=7.6 Hz, 1H), 
7.26 (d, J=7.6 Hz, 2H), 7.18 (d, J=8.0 Hz, 1H), 6.90 (d, J=8.0 Hz, 1H), 4.94-4.90 (m, 1H), 
3.48-3.41 (m, 2H), 3.35-3.29 (m, 2H), 2.85 (s, 3H), 2.35-2.27 (m, 2H), 2.22-2.14 (m, 2H). 
13C-NMR (CD3OD, 100 MHz): δ 160.02, 157.66, 154.69, 151.71, 140.26, 130.67, 130.62, 
129.16, 127.21, 122.79, 120.29, 106.62, 106.19, 70.09, 41.99, 28.26, 12.05. Calculated exact 
mass for the protonated molecule (C21H22NO4): 352.1549; measured accurate mass (ESI): 
352.1545. LC-MS purity: 100%, Rt = 12.17 min.  
 
    Prototypical Procedure for amide analogues 9-13. N-isopropyl-3-methyl-4-(piperidin-4-
yloxy)benzofuran-2-carboxamide(9) To a solution of compound I-2 (30 mg, 0.08 mmol) in 
DMF/DCM (2 mL, 1:1) was sequentially added DIPEA (15 µL, 0.088 mmol), PyBOP (46 
mg, 0.088 mmol). The above mixture was stirred at room temperature for 30 minutes, 
followed by the addition of isopropylamine (7.6 µL, 0.088 mmol). The resulting mixture was 
further stirred at room temperature for 3 hours. After that, the reaction mixture was diluted 
with DCM (15 mL) and partitioned with 0.5M NaOH solution (15 mL), and then the aqueous 
layer was further extracted by DCM (10 mL). The combined organic layers were washed 
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brine, dried over anhydrous sodium sulphate and concentrated in vacuo. The residue was 
purified by column chromatography over silica gel, to afford the N-Boc precursor. 
The Boc-deprotection in DCM (2 mL) containing 5% TFA was carried out according to the 
preparation of compound 2, to afford the title compound as a white solid (11.5 mg, 34% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.37 (t, J=8.4 Hz, 1H), 7.16 (d, J=8.4 Hz, 
1H), 6.87 (d, J=8.4 Hz, 1H), 4.98-4.93 (m, 1H), 4.30-4.96 (m, 1H), 3.46-3.40 (m, 2H), 3.32-
3.29 (m, 2H), 2.80 (s, 3H), 2.32-2.25 (m, 2H), 2.21-2.13 (m, 2H), 1.29 (d, J=6.4 Hz, 6H). 
13C-NMR (CD3OD, 100 MHz): δ 161.52, 156.45, 154.30, 143.11, 129.19, 123.31, 120.78, 
106.62, 106.05, 69.78, 42.32, 41.92, 28.23, 22.58, 11.52. Calculated exact mass for the 
protonated molecule (C18H25N2O3): 317.1865; measured accurate mass (ESI): 317.1867. LC-
MS purity: 100%, Rt = 10.75 min.  
 
    Procedure for alkenes 15 and 16 and alkyl 18. 4-({3-Methyl-2-[(E)-2-phenylethenyl]-1-
benzofuran-4-yl}oxy)piperidine(16) To a mixture of compound I-4 (50 mg, 0.14 mmol) and 
benzyltriphenyl phosphonium bromide (65 mg, 0.15 mmol) in DCM/water (2 mL, 1:1), 10M 
of NaOH solution (50 µL) was added. The resulting mixture was stirred at room temperature 
for 1 hour. After that, the reaction mixture was diluted with DCM (20 mL) and washed 
sequentially with water and brine (15 mL each). The organic layer was concentrated to give 
the mixture of the cis/trans N-Boc precursors.  
The Boc-deprotection in DCM (2 mL) containing 5% TFA was carried out according to the 
preparation of compound 2, to isolate the title compound as 1st major fraction from 
preparative HPLC (white solid, 4.9 mg, 8% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 
7.41 (d, J=8.0 Hz, 2H), 7.34-7.26 (m, 3H), 7.17 (t, J=8.0 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H), 
6.78 (d, J=8.0 Hz, 1H), 6.72 (d, J=12.4 Hz, 1H), 6.51 (d, J=12.4 Hz, 1H), 4.89-4.85 (m, 1H), 
3.44-3.37 (m, 2H), 3.31-3.26 (m, 2H), 2.54 (s, 3H), 2.32-2.22 (m, 2H),  2.19-2.11 (m, 2H). 
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13C-NMR (CD3OD, 125 MHz): δ 156.93, 152.96, 150.05, 138.72, 132.03, 130.13, 128.88, 
128.52, 127.58, 126.68, 120.99, 116.34, 106.39, 105.56, 69.57, 41.95, 28.32, 11.06. 
Calculated exact mass for the protonated molecule (C22H24NO2): 334.1807; measured 
accurate mass (ESI): 334.1813. LC-MS purity: 96% (trans:cis = 3:1), Rt = 13.22 min.  
 
4-({3-methyl-2-[(Z)-2-phenylethenyl]-1-benzofuran-4-yl}oxy)piperidine(15) The title 
compound was isolated as 2nd major fraction from the above preparative HPLC (off-white 
solid, 14.6 mg, 23% overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.58 (d, J=7.2 Hz, 2H), 
7.38 (t, J=8.0 Hz, 2H), 7.27 (t, J=7.2 Hz, 1H), 7.23-7.18 (m, 3H), 7.07 (d, J=8.0 Hz, 1H), 6.78 
(d, J=8.0 Hz, 1H), 4.90-4.82 (m, 1H), 3.46-3.40 (m, 2H), 3.32-3.27 (m, 2H), 2.53 (s, 3H), 
2.35-2.22 (m, 2H), 2.21-2.12 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 157.20, 153.02, 
150.95, 138.43, 129.81, 129.62, 128.88, 127.58, 126.80, 121.67, 115.10, 114.66, 106.55, 
105.43, 69.62, 41.94, 28.34, 10.52. Calculated exact mass for the protonated molecule 
(C22H24NO2): 334.1807; measured accurate mass (ESI): 334.1799. LC-MS purity: 97%, Rt = 
13.64 min.  
 
4-{[3-Methyl-2-(2-phenylethyl)-1-benzofuran-4-yl]oxy}piperidine(18) A mixture of 
compound 15 (13 mg, 0.039 mmol), palladium on carbon (10% w/w, 5 mg, 0.008 mmol) and 
1,4-cyclohexadiene (70 µL) in ethanol (1 mL) was stirred at 80 ˚C for 4 hours. The reaction 
mixture was then concentrated in vacuo and the residue was purified by semi-preparative 
reverse phase HPLC to give the title compound as colourless oil (6.6 mg, 38% yield). 1H-
NMR (CD3OD, 500 MHz): δ 7.23 (t, J=8.0 Hz, 2H), 7.18-7.11 (m, 4H), 7.03 (d, J=8.0 Hz, 
1H), 6.74 (d, J=8.0 Hz, 1H), 4.85-4.81 (m, 1H), 3.40-3.35 (m, 2H), 3.30-3.25 (m, 2H), 3.00 
(brs, 4H), 2.25-2.19 (m, 2H), 2.15-2.09 (m, 2H), 2.11 (s, 3H). 13C-NMR (CD3OD, 125 MHz): 
δ 157.06, 153.11, 152.38, 142.37, 129.55, 129.31, 127.08, 125.06, 121.20, 111.15, 106.34, 
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105.55, 69.41, 41.90, 35.44, 29.07, 28.31, 10.17. Calculated exact mass for the protonated 
molecule (C22H26NO2): 336.1964; measured accurate mass (ESI): 336.1964. LC-MS purity: 
100%, Rt = 13.30 min.  
 
    Procedure for ethers 19 and 21. 4-{[3-Methyl-2-(phenoxymethyl)-1-benzofuran-4-yl]oxy} 
piperidine (19) To a stirred solution of compound I-5 (30 mg, 0.06 mmol), phenol (14.1 mg, 
0.15 mmol) and triphenylphosphine (39 mg, 0.15 mmol) in anhydrous THF (2 mL) was 
added DIAD (29 µL, 0.15 mmol) at room temperature. The resulting mixture was stirred at 
the same temperature for 4 hours, and then concentrated in vacuo. The residue was purified 
by column chromatography over silica gel, to afford the N-trityl precursor. 
The trityl-deprotection was carried out in DCM (1 mL), containing 0.1% of TFA and 0.2% 
of water, at room temperature for 12 hours. After that, the reaction mixture was concentrated 
in vacuo and the residue was purified by semi-preparative reverse phase HPLC, with no TFA 
in the mobile phases, to afford the title compound as colorless oil (0.4 mg, 2% overall yield). 
1H-NMR (CD3OD, 400 MHz): δ 7.32-7.28 (m, 2H), 7.24 (t, J=8.0 Hz, 1H), 7.09 (d, J=8.0 Hz, 
1H), 7.04 (d, J=8.0 Hz, 2H), 6.98 (t, J=8.0 Hz, 1H), 6.81 (d, J=8.0 Hz, 1H), 5.15 (s, 2H), 
4.96-4.89 (m, 1H), 3.43-3.38 (m, 2H), 3.30-3.26 (m, 2H), 2.48 (s, 3H), 2.30-2.22 (m, 2H), 
2.20-2.11 (m, 2H). 13C-NMR (CD3OD, 125 MHz): δ 159.96, 153.18, 148.70, 138.03, 130.54, 
126.75, 122.40, 120.63, 116.18, 115.81, 106.33, 105.89, 69.55, 61.90, 41.98, 28.34, 10.50. 
Calculated exact mass for the protonated molecule (C21H24NO3): 338.1756; measured 
accurate mass (ESI): 338.1772. LC-MS purity: 100%, Rt = 12.44 min.  
 
    4-({2-[(Benzyloxy)methyl]-3-methyl-1-benzofuran-4-yl}oxy)-piperidine (21) A solution of 
I-4 (30 mg, 0.06 mmol) and sodium hydride (60% w/w, 7.2 mg, 0.18 mmol) in anhydrous 
DMF was stirred at room temperature for 30 minutes, and then treated with benzyl bromide 
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(10.7 µL, 0.09 mmol). The resulting mixture was further stirred at room temperature for 12 
hours. After that, the reaction mixture was quenched with 100 µL of cold water, diluted with 
EtOAc (20 mL) and sequentially washed with water and brine (each for 20 mL). The organic 
layer was concentrated in vacuo and the residue was purified by column chromatography 
over silica gel, to give the N-trityl precursor. 
    The trityl-deprotection was carried out in DCM (1 mL), containing 0.1% of TFA and 0.2% 
of water, at room temperature for 12 hours. After that, the reaction mixture was concentrated 
in vacuo and the residue was purified by semi-preparative reverse phase HPLC, with no TFA 
in the mobile phases, to afford the title compound as colourless oil (2 mg, 10% overall yield). 
1H-NMR (CD3OD, 400 MHz): δ 7.40-7.28 (m, 5H), 7.23 (t, J=8.0 Hz, 1H), 7.09 (d, J=8.0 Hz, 
1H), 6.81 (d, J=8.0 Hz, 1H), 4.91-4.85 (m, 1H), 4.64 (s, 2H), 4.60 (s, 2H), 3.46-3.39 (m, 2H), 
3.30-3.27 (m, 2H), 2.43 (s, 3H), 2.30-2.22 (m, 2H), 2.20-2.12 (m, 2H). 13C-NMR (CD3OD, 
125 MHz): δ 156.06, 151.72, 148.30, 137.87, 128.02, 127.62, 127.45, 125.19, 119.22, 
114.14, 104.84, 104.45, 71.65, 68.06, 61.44, 40.53, 26.90, 9.14. Calculated exact mass for the 
protonated molecule (C22H26NO3): 352.1913; measured accurate mass (ESI): 352.1909. LC-
MS purity: 100%, Rt = 12.34 min.  
 
    (2E)-1-[3-Methyl-4-(piperidin-4-yloxy)-1-benzofuran-2-yl]-3-phenylprop-2-en-1-one 
(23). Prepared from a solution of compound I-6 (190 mg, 1.0 mmol), t-Butyl 4-
hydrxypiperidine-1-carboxylate (500 mg, 2.5 mmol), triphenylphosphine (657 mg, 2.5 mmol) 
and DIAD (480 µL, 2.5 mmol) in anhydrous THF (4 mL) according to the procedure of 
making compound I-1, t-Butyl 4-[(2-acetyl-3-methyl-1-benzofuran-4-yl)oxy]piperidine-1-
carboxylate was obtained as a light yellow solid (318 mg).  
    Above solid (50 mg, 0.13 mmol) and benzaldehyde (15 µL, 0.15 mmol) in ethanol (1 mL) 
was added 0.25 M NaOH solution (1 mL). The mixture was stirred at room temperature for 3 
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hours, and then diluted with 20 mL EtOAc, followed by the wash with water and brine (20 
mL each). The organic layer was dried over anhydrous sodium sulphate and concentrated in 
vacuo. The residue was purified by column chromatography over silica gel, to give the N-Boc 
precursor.  
The N-Boc deprotection was carried out in DCM containing 5% TFA (2 mL) according to 
the preparation of compound 2, to afford the title compound as a yellow solid (14.7 mg, 24% 
overall yield). 1H-NMR (CD3OD, 400 MHz): δ 7.86-7.75 (m, 4H), 7.51-7.45 (m, 4H), 7.24 
(d, J=8.0 Hz, 1H), 6.89 (d, J=8.0 Hz, 1H), 5.02-4.93 (m, 1H), 3.50-3.39 (m, 2H), 3.33-3.27 
(m, 2H), 2.88 (s, 3H), 2.36-2.24 (m, 2H), 2.24-2.12 (m, 2H). 13C-NMR (CD3OD, 100 MHz): 
δ 183.19, 157.14, 154.95, 148.89, 145.04, 136.18, 131.91, 130.81, 130.14, 129.73, 127.50, 
123.26, 120.94, 106.64, 106.38, 70.04, 41.99, 28.26, 12.17. Calculated exact mass for the 
protonated molecule (C23H24NO3): 362.1756; measured accurate mass (ESI): 362.1750. LC-
MS purity: 97%, Rt = 13.17 min.  
 
    4-{[2-(Phenylmethane)sulfonyl-1-benzofuran-4-yl]oxy}piperidine(24). A mixture of t-
Butyl 4-{[2-(benzylsulfanyl)-1-benzofuran-4-yl]oxy} piperidine-1-carboxylate (20 mg, 0.046 
mmol) and 3-chloroperbenzoic acid (77% w/w, 16 mg, 0.07 mmol) in DCM (1 mL) was 
stirred at room temperature for 1 hour. The reaction mixture was concentrated in vacuo, to 
give the N-Boc precursor without further purification.  
    The N-Boc deprotection was carried out in DCM containing 5% TFA (2 mL) according to 
the preparation of compound 2, to afford the title compound as pink oil (8.0 mg, 36% overall 
yield). 1H-NMR (CD3OD, 400 MHz): δ 7.52 (t, J=8.0 Hz, 1H), 7.46 (s, 1H), 7.35-7.21 (m, 
6H), 6.99 (d, J=8.0 Hz, 1H), 4.98-4.92 (m, 1H), 4.72 (s, 2H), 3.48-3.39 (m, 2H), 3.29-3.19 
(m, 2H), 2.28-2.18 (m, 2H), 2.14-2.07 (m, 2H). 13C-NMR (CD3OD, 100 MHz): δ 157.59, 
151.61, 148.00, 130.60, 129.39, 128.55, 128.22, 127.77, 117.35, 112.47, 106.75, 105.11, 
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68.95, 60.60, 40.31, 26.78. Calculated exact mass for the protonated molecule (C20H22NO4S): 
372.1270; measured accurate mass (ESI): 372.1263. LC-MS purity: 100%, Rt = 10.91 min.  
 
BIOLOGY 
Enzyme Inhibition Assay. Measurement of the ability of compounds to inhibit NMTs was 
performed in 96-well plates using a modification of the scintillation proximity assay 
platform:39 each well (in total 100 µL) contained variable amounts of an inhibitor, 9.4 ng of 
purified PfNMT (4.8 ng for PvNMT, 19.2 ng for PvNMTY211A, 5.1 ng for HsNMT1 and 20.4 
ng for HsNMT1Y296A), 62.5 nM 3H-Myristoyl-CoA (8 Ci/mmol, purchased from Perkin 
Elmer) and 500 nM of the peptide substrate (GLYVSRLFNRLFQKK(Biotin)-NH2) in 4% 
DMSO buffer (30 mM Tris, pH 7.4, 0.5 mM EGTA, 0.5 mM EDTA, 2.5 mM DTT, 0.1% 
Triton X-100). Incubation was allowed to proceed for 30 min at 37°C, followed by the 
addition of 100 µL 1 mg/mL streptavidin PVT bead (purchased from Perkin Elmer) in a stop 
solution (200 mM phosphoric acid / NaOH, pH 4, 750 mM MgCl2, 0.05% (w/V) BSA, 0.01% 
(w/V) NaN3) to terminate the reaction. Overnight settling of the beads resulted in an accurate 
reading, with signal-to-noise ratio at least 20. The instrument used for counting is a Plate 
Chameleon multi-label reader (Hidex Oy, Finland). The readout of [3H]-myristoylated 
peptide in the reaction lacking an inhibitor was defined as 100% activity (positive control), 
and that from the reaction with no enzyme was defined as 0% (negative control). The effect 
of an inhibitor at the single concentration was calculated as a percentage of the enzyme 
activity left (% activity left = (readout-negative) / (positive-negative) x 100%). In terms of 
the IC50 determination, the inhibitory activity of an inhibitor was measured according to the 
method described above with the concentrations ranging from 500 µM to 2 nM and the 50% 
inhibitory concentration (IC50) of an inhibitor was calculated by a nonlinear regression 
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analysis using GraFit 7.0.1 version (Erithacus Software Limited, UK). The assays were 
carried out in duplicate.  
 
P. falciparum Inhibition Assay. Measurement of the ability of compounds to kill parasites 
was performed in 96-well plates using a modification of the fluorescent-activity cell sorting 
(FACS) assay platform:40, 41 each well (in total 100 µL, 0.5% DMSO) contained synchronous 
cultures of late trophozoite-stage parasites (1% parasitemia and 2% hematocrit) and variable 
concentrations of an inhibitor. The mixture was incubated at 37 ˚C for a full 48-hour growth 
cycle. Aliquots of 50 µL were removed from each well, added to 500 μL freshly diluted 
hydroethidine (HE, 1:200 dilution of 10 mg/mL DMSO stock in PBS) and incubated for 20 
min at 37°C. Samples were then diluted with 1 mL PBS to enable appropriate cell counts 
(50,000) and stored on ice. Parasites cultured in the absence of an inhibitor and non-infected 
red blood cells were used as positive and negative controls respectively. Parasitemia was 
measured using a FACS Calibur flow cytometer. Growth inhibition at each concentration was 
calculated as % inhibition = [1-(readout-negative control) / (positive-negative control)] x 
100%. To determine the EC50 of an inhibitor, its activity at a range of concentrations from 10 
µM down to 0.31 µM and the 50% inhibitory concentration (EC50) of an inhibitor was 
calculated by a nonlinear regression analysis using GraFit 7.0.1 version (Erithacus Software 
Limited, UK). All assays were carried out in triplicate.  
 
 
CRYSTALLOGRAPHY 
    Protein expression, purification and crystallization. For HsNMT1, a clone directing the 
synthesis of a protein without the first 108 amino acid residues corresponding to the NMT 
catalytic domain was expressed in E. coli and purified as described in reference34. PvNMT 
expression and purification followed protocols as described in reference38. Mutagenesis of 
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PvNMT Y211 and HsNMT Y296 residues to alanine was performed using a QuikChange 
Lightning site-directed mutagenesis kit (Stratagene). Initial crystals of a binary complex with 
a non-hydrolysable cofactor (PvNMT-NHM) were grown from a solution of protein 
(6 mg/ml) containing 1/20th volume of S-(2-oxo) pentadecyl-coenzyme A (NHM, 10 mM in 
50% DMSO) and an equal volume of IndexScreen (Hampton) solution F7 (0.2 M ammonium 
sulphate and 25% (w/v) PEG 3350 in 0.1 M Bis-Tris buffer, pH 6.5). The crystals belong to 
the orthorhombic space group P212121.The structure was solved by molecular replacement in 
the program MOLREP42 using the protein coordinates of NMT from L. donovani (PDB code 
2WUU)43 as the search model. Three solutions (a trimer) were found, corresponding to a 
Matthew’s coefficient of 2.22 Å3/Da and a solvent content of 44.5%, and this trimer was used 
as the basis for structure determination of ternary complexes of PvNMT-NHM containing 
ligands (Table S5, Supporting information). For crystallization of the ligand complexes, 
PvNMT was incubated overnight at 4°C with NHM as above plus solid ligand (compounds 
25 and 26) or 1/20th volume ligand (compounds 13 and 22,10 mM in 50% DMSO). Crystals 
were grown by the vapour diffusion method, typically from sitting drops consisting of 0.3 µL 
protein mixture (after centrifugation to pellet any solid material) and 0.3 µL of reservoir 
solution containing 0.2 M ammonium sulphate, 24-26% (w/v) PEG 3350, in 0.1 M Bis-Tris 
or MES buffer, pH 6.0-6.5 equilibrated against 0.1 mL reservoir solution in 48-well plates at 
20°C. Crystals were vitrified directly in liquid nitrogen before storage. 
 
    Data collection, processing and refinement. X-ray diffraction data were collected on 
synchrotron beamlines at the Diamond Light Source (DLS), Oxford and processed using 
XDS44 and SCALA45 implemented within xia2.46 Data collection and refinement statistics are 
summarized in Supplementary Table S5. For Rfree calculations, 5% of the data were excluded 
and the Rfree flags for each ternary complex structure solution were copied from the binary 
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complex structure (PvNMT-NHM). Rigid Body refinement using maximum likelihood 
methods implemented in REFMAC47 was followed by a cycle of model building and 
adjustment using COOT48 and five cycles of refinement using anisotropic temperature 
factors. Electron density maps from this early stage of refinement calculated using phases 
unbiased by contributions from ligand (‘omit’ maps) are presented in Figure S3, Supporting 
Information. Complete chains (corresponding to residues 26 - 410, numbering as in full-
length protein) can be traced for two of the three molecules in the asymmetric unit. N-
terminal residues (remaining from the tag) in all three chains and loop residues 227 - 238 in 
chain C have not been modeled and these are assumed to be disordered. The protein structure 
models display good geometry with 95.9% of the residues in the preferred region of the 
Ramachandran plot, with an additional 3.9% in allowed regions and 0.2% (corresponding to 
two residues in chain C) as outliers. For ligand co-crystal structures, three residues (F336 in 
all three chains) also appear in outlying regions of the plot. The coordinates and structure 
factor files have been deposited in the Protein Data Bank under the accession codes 4B10 
(PvNMT-NHM), 4B11 (PvNMT-NHM-13), 4B12 (PvNMT-NHM-22), 4B13 (PvNMT-
NHM-25) and 4B14 (PvNMT-NHM-26). 
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